Meeting
2024 ASCO Genitourinary Cancers Symposium
11-Ketotestosterone and time to castration resistance in patients with recurrent non-metastatic prostate cancer receiving androgen deprivation therapy.
Authors
Chantal Guillemette
CHU de Québec - Université Laval, Québec, QC, Canada
Chantal Guillemette , Cylia Dahmani , Patrick Caron , David Simonyan , Louis Lacombe , Armen G. Aprikian , Fred Saad , Michel Carmel , Simone Chevalier , Eric Levesque
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 209)
DOI
10.1200/JCO.2024.42.4_suppl.209
Abstract #
209
Poster Bd #
J17
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Anticancer activity of the selective CYP17A1 inhibitor, VT-464, in preclinical models of castrate-resistant prostate cancer.
First Author: Paul Toren
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer: Experience from a safety-net hospital serving a racially and ethnically diverse patient population.
First Author: Alyssa Liang
Poster
2019 ASCO Annual Meeting
Cognitive effects of androgen receptor (AR) directed therapies for advanced cancer of the prostate (COGCaP).
First Author: Julie Van
Poster
2019 Genitourinary Cancers Symposium
Measurement science of the androgen receptor splice variant-7 protein in primary and castration-resistant prostate cancer tissue.
First Author: Adam Sharp